New Leaf Venture Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

New Leaf Venture Partners’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$5.87M	Hold	141,000	–	–	13.64%	3
2025 Q2	$4.06M	Hold	141,000	–	–	7.66%	4
2025 Q1	$4.73M	Hold	141,000	–	–	10.53%	3
2024 Q4	$7.21M	Hold	141,000	–	–	9.64%	3
2024 Q3	$7.21M	Hold	141,000	–	–	7.41%	3
2024 Q2	$6.32M	Hold	141,000	–	–	7.68%	3
2024 Q1	$6.6M	Hold	141,000	–	–	5.78%	4
2023 Q4	$5.02M	Hold	141,000	–	–	4.04%	6
2023 Q3	$4.19M	Hold	141,000	–	–	5.38%	6
2023 Q2	$2.54M	Hold	141,000	–	–	2.18%	7
2023 Q1	$2.26M	Hold	141,000	–	–	1.87%	10
2022 Q4	$2.58M	Hold	141,000	–	–	1.87%	10
2022 Q3	$2.77M	Hold	141,000	–	–	1.64%	11
2022 Q2	$2.63M	Hold	141,000	–	–	1.7%	12
2022 Q1	$3.1M	Hold	141,000	–	–	1.53%	14
2021 Q4	$4.01M	Hold	141,000	–	–	1.45%	15
2021 Q3	$2.97M	Hold	141,000	–	–	0.86%	16
2021 Q2	$44.3M	Hold	141,000	–	–	11.37%	2
2021 Q1	$2.15M	Hold	141,000	–	–	0.5%	16
2020 Q4	$1.99M	Hold	141,000	–	–	0.46%	14
2020 Q3	$2.21M	Hold	141,000	–	–	0.89%	15
2020 Q2	$2.47M	Hold	141,000	–	–	0.71%	15
2020 Q1	$2.07M	Hold	141,000	–	–	0.62%	16
2019 Q4	$3.54M	Hold	141,000	–	–	0.77%	14
2019 Q3	$2.12M	Sell	141,000 -26,700	-16%	-$519K	0.64%	17
2019 Q2	$4.19M	Hold	167,700	–	–	1.12%	14
2019 Q1	$3.82M	Hold	167,700	–	–	1.05%	14
2018 Q4	$5.03M	Hold	167,700	–	–	1.38%	13
2018 Q3	$4.8M	Buy	+167,700	New	+$4.98M	0.87%	14

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

New Leaf Venture Partners's CRNX Position: Q3 2025 in Review

New Leaf Venture Partners held its Crinetics Pharmaceuticals (CRNX) position steady in Q3 2025 at 141,000 shares worth $5.87M. The position accounts for 13.64% of the portfolio, ranked #3.

New Leaf Venture Partners first reported a position in CRNX in Q3 2018 and has held it in 29 quarters since. The position peaked at $44.3M in Q2 2021. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

New Leaf Venture Partners held 141,000 shares of Crinetics Pharmaceuticals worth $5.87M as of Q3 2025.
New Leaf Venture Partners left its Crinetics Pharmaceuticals share count unchanged in Q3 2025.
Crinetics Pharmaceuticals made up 13.64% of New Leaf Venture Partners's portfolio in Q3 2025, its #3 holding.
New Leaf Venture Partners first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 29 quarters since.
New Leaf Venture Partners's Crinetics Pharmaceuticals position peaked at $44.3M in Q2 2021.
225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on New Leaf Venture Partners's 13F filing for Q3 2025, filed 14 Nov 2025.